Healthplus.ai Raises €2.3M to Predict and Prevent Surgical Complications

AMSTERDAM, the Netherlands, Nov. 27, 2025 — Healthplus.ai, an emerging Dutch digital HealthTech and AI startup, has raised €2.3M to further accelerate the development of its AI system that predicts post-surgery infection risk for individual patients and proposes mitigation measures to support surgical teams in proactively preventing post-operative complications. The investment was led by Elevating Capital, co-led by LUMO Labs, joined by ROM InWest, Pathena Venture Capital from Portugal, and Leistone (Renza Family).

The startup’s ISO- and CE-certified AI system, PERISCOPE®, aims to reduce (the impact of) complications, shorten recovery time, and reduce hospital costs.

“With this late-seed investment, we’re strengthening our ability to bring clinically validated, regulatory-approved AI into everyday hospital practice. Our focus remains on close collaboration with surgeons, clinicians, and hospital IT teams to ensure that predictive insights truly improve patient outcomes,” said Dr Bart Geerts, CEO and founder of Healthplus.ai.

Healthplus.ai will deploy the new capital to accelerate further roll-out across Europe and the U.S. through FDA clearance, advanced interoperability and integrations with leading electronic health record (EHR) systems, including Epic, Cerner, and ChipSoft, and further development of its AI risk models across all perioperative stages and types of complications.

Roel Waals, Founding Partner of Elevating Capital, new investor leading this key round, said; “We see in this team strong execution capabilities, a scalable business model, and a clear contribution to the future of healthcare.” Marcel Broersma, also Founding Partner of Elevating Capital, adds; “The investment in Healthplus.ai fits seamlessly within our strategy to invest in technology-driven companies with a demonstrable social impact. Healthplus.ai combines medical expertise with artificial intelligence to make clinical risks predictable and to improve the quality and efficiency of healthcare processes.”

“AI is critical to reform our healthcare system and to relieve the increasing strain on nurses, doctors, and budgets, while upholding or even improving the high level of care we are used to,” commented Andy Lurling, founding partner of LUMO Labs, investor in Healthplus.ai since early 2022. “The adoption of MedTech AI requires not just two of the things Healthplus.ai does extremely well, that is, understanding the need of the user and proving impact. It also requires two things not all investors are too keen on, regulation and certification, processes that can be lengthy, unpredictable, and costly,” Lurling continued. “This is why raising capital, even for the most successful MedTech AI startup, can be exceptionally challenging, especially in more risk-averse parts of the world, like here. We are very excited to have these incredibly committed and experienced investors joining the ranks. It is a true testament to Healthplus.ai stamina and achievements so far, and to their immense potential going forward.”

“The ability to accurately predict infections in hospitalized patients is critical both to better protect their lives and to manage the cost of—and risk of resistance to—antibiotic use in a hospital setting. We are very happy to join the supporting squad of Healthplus.ai,” added Antonio Murta, Co-Managing Partner and CEO of PATHENA.

“Healthplus.ai demonstrates that true healthcare innovation is not only about increasing efficiency but also about improving patient outcomes. This aligns perfectly with Leistone B.V.’s investment strategy: supporting technology-driven ventures that create real impact. We believe Healthplus.ai is a driver of a smarter, safer, and future-proof healthcare system,” said Tim Heijink, General Manager at Leistone.

“We are excited about our investment in the North Holland–based Healthplus.ai. With unprecedented accuracy, Healthplus.ai predicts postoperative infections, enabling faster patient recovery, more efficient workflows for specialists, and easing the burden on the healthcare system. We are proud that through this investment we can contribute to a future-proof healthcare system,” said Sara Schaafsma, Investment Manager at ROM InWest.

Healthplus.ai is currently active in the Netherlands, Belgium, Denmark, and the UK and is preparing to expand its footprint across the Nordics and North America, with initial pilots in the U.S. underway.